Mireia Uribe-Herranz PhD

I am a cancer immunotherapy researcher @hospitalclinic / Microbiota / Ph.D in immunology.

[immunoclinicbcn @immunoclinicbcn]

Artículo completo: https://t.co/YF3aPrI9o7

[immunoclinicbcn @immunoclinicbcn]

🦠🧬Sabes como puede afectar la microbiota al sistema inmunitario y a la terapia CAR-T? Nuestra compañera @MireiaUribe nos cuenta en @som3cat su última publicacion➡️ @hospitalclinic @idibaps
https://t.co/8xoteo3uvU

[Mireia Uribe-Herranz PhD @MireiaUribe]

Gràcies @324cat @som3cat @martarrufat per fer-vos ressò del nostre estudi #microbiota #immunotherapy #CARTcell

[IDIBAPS @idibaps]

📺Recuperem el reportatge de TV3 sobre aquest nou descobriment:

Un estudi del #CLÍNIC-#IDIBAPS revela que la microbiota pot predir i potenciar la resposta dels pacients a una de les més innovadores immunoteràpies contra el càncer
@324cat @martarrufat @MireiaUribe @hospitalclinic

[IDIBAPS @idibaps]

Aquesta setmana a l'IDIBAPS...

Un estudi liderat pel #CLÍNIC-#IDIBAPS revela que la microbiota pot predir i potenciar la resposta dels pacients a la teràpia CAR-T en mieloma múltiple

👉https://t.co/WXB6mBygFK

[Mireia Uribe-Herranz PhD @MireiaUribe]

Special thank to patients and their families, and all coauthors for making this study possible.

[Mireia Uribe-Herranz PhD @MireiaUribe]

Our latest work is now out at @BCD_AACR https://t.co/9ukydz5Fli Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma. @idibaps @hospitalclinic @Manel_JuanOtero @fdezdelarrea @ainitaoliver @BiosferTeslab

[Mireia Uribe-Herranz PhD @MireiaUribe]

The study integrates microbial profiles into response models, providing a tool to identify patients with multiple myeloma who may benefit from BCMA CART-cell therapy optimization by ID bacterial taxa and metabolites associated with CAR T-cell persistence and therapeutic outcomes

[Blood Cancer Discovery @BCD_AACR]

Online First: Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma https://t.co/CAmHKW1tIl

[Blood Cancer Discovery @BCD_AACR]

Now online: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma https://t.co/OzPjaPx21T

[IDIBAPS @idibaps]

🆕A study led by the #CLÍNIC-#IDIBAPS reveals that the microbiota can predict and enhance patient response to CAR T-cell therapy in multiple myeloma

This opens the door to personalized treatments and new combined therapeutic strategies

👉https://t.co/KnsdZJoIgm

[IDIBAPS @idibaps]

The group in ➡️Immunogenetics and immunotherapy in the autoinflammatory and immune response⬅️ led by Manel Juan creates immunotherapy tools to generate response against diseases such as #cancer or #autoimmunity diseases

https://t.co/U77AM7pI8i

[SoniaGuedan @GuedanS]

💼👩‍🔬 Join our team! If you have experience in autoimmune diseases or cancer immunotherapy (CAR-T cells), plus skills in cell culture, animal models, and/or molecular biology, check out these positions:

🔬 Technician: https://t.co/WWZcmRtNfC
🧪 Postdoc: https://t.co/aAsJv8HY76

[Chromatin biology Lab @vaquerolab]

Happy to announce that our work @vaquerolab @CarrerasIJC on the SIRT7/PAX5 interplay in B-cell development has been published in the Dec issue of @NatImmunol. Huge thanks to collaborators and funding agencies for their contributions.
Sirtuins rule!! 🦾
https://t.co/7qCmltQXjg

[SoniaGuedan @GuedanS]

Our latest work is out in @MolTherapy! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation.
➡️ https://t.co/yMhjCAjyaq

[SoniaGuedan @GuedanS]

📰 Carl June just received the @AbarcaPrize from the @HMHOSPITALES Foundation for the development of CAR-T cells against blood cancers.

On Sunday, @LaVanguardia published this interview to Carl June by @JosepCorbella (in Spanish):
https://t.co/Qb2gvMcVB7

[Hospital Clínic @hospitalclinic]

És la 2a teràpia avançada del #CLÍNIC-@idibaps que serà autoritzada per l'AEMPS per a pacients amb malalties hematològiques

Ho hem presentat amb el Conseller @manelbalcells, @jmcampis, @UrbanoIspizuaMD, Elias Campo, @Manel_JuanOtero, @fdezdelarrea, @ignasilopezv de @FundlaCaixa

[Hospital Clínic @hospitalclinic]

🏥 Llum verda al CAR-T ARI0002h desenvolupat pel #CLÍNIC-@idibaps per a pacients amb mieloma múltiple en recaiguda.

✅ El Comitè de l'@AEMPSGOB ha donat el vistiplau per aprovar-lo com a medicament de teràpia avançada de fabricació no industrial.

👉https://t.co/Jkoks7plEM

[Carlos Fernandez de Larrea @fdezdelarrea]

Just online! Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells https://t.co/YtUwd935vG @BrJHaem @idibaps @hematoclinicbcn @hospitalclinic @immunoclinicbcn @InakiOdlp @ainitaoliver @BrunoPaiva_UNAV @vivamarta

[SoniaGuedan @GuedanS]

Excited to share that our paper is now out in @NatureComms! We explore how CAR affinity influences CAR-T cell sensitivity to PD1/PD-L1 inhibition. Huge congrats to Irene Andreu and @Alba_rodriguezg for their exceptional work! @idibaps @hospitalclinic
https://t.co/HYZI10uMQz

[SantanaCodina lab @SantanaCodina]

Extended call! We are still looking for a talented postdoc to join our team. If you are excited about pancreatic cancer, metabolism and immune modulation , this is for you 👇🏻

https://t.co/4SblGecx8D